The facts
The SAFER-study is the world’s largest screening for Atrial Filibration and covers a total of 120 000 patients aged over 65 in 300 general practises within NHS across England and is financed by National Institute for Health Research. The study is led by researchers from Cambridge University since 2018.
The patients will be loaned a handheld ECG device, provided by Zenicor, to measure ECG twice a day at home for two weeks. Patients in 100 practises will undergo the screening and the other 200 will not. Both set of patients will be followed up during five years, whether the screenings and treatments leads to fewer strokes, heart attacks and deaths. Patients who are found to have atrial fibrillation by the screening within this study will be offered treatment with anticoagulant drugs.
Aktuellt
SENASTE
